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Background: Angiogenesis is involved in tumor growth, macular degeneration,
retinopathy and other diseases. Vascular endothelial growth factor (VEGF)
stimulates angiogenesis by binding to specific receptors (VEGFRs) on the
surface of vascular endothelial cells. VEGFRs are receptor tyrosine kinases that,
like the platelet-derived growth factor receptors (PDGFRs), contain a large
insert within the kinase domain. 
Results: We report here the generation, kinetic characterization, and 2.4 Å
crystal structure of the catalytic kinase domain of VEGF receptor 2 (VEGFR2).
This protein construct, which lacks 50 central residues of the 68-residue kinase
insert domain (KID), has comparable kinase activity to constructs containing the
entire KID. The crystal structure, determined in an unliganded phosphorylated
state, reveals an overall fold and catalytic residue positions similar to those
observed in other tyrosine-kinase structures. The kinase activation loop,
autophosphorylated on Y1059 prior to crystallization, is mostly disordered;
however, a portion of it occupies a position inhibitory to substrate binding. The
ends of the KID form a β-like structure, not observed in other known tyrosine
kinase structures, that packs near to the kinase C terminus.
Conclusions: The majority of the VEGFR2 KID residues are not necessary for
kinase activity. The unique structure observed for the ends of the KID may also
occur in other PDGFR family members and may serve to properly orient the KID
for signal transduction. This VEGFR2 kinase structure provides a target for
design of selective anti-angiogenic therapeutic agents. 
Introduction
Many physiological events including embryogenesis, organ
development, estrus, and wound healing require vascular
growth and remodeling [1,2]. In addition to these benefi-
cial processes, angiogenesis is also involved in the prolifer-
ation of disease states such as tumor growth, metastasis,
psoriasis, rheumatoid arthritis, macular degeneration and
retinopathy [3–7]. Of the signaling pathways known to
influence vascular formation, that involving vascular endo-
thelial growth factor (VEGF) has been shown to be essen-
tial and selective for vascular endothelial cells [8–10]. The
therapeutic potential of inhibiting the VEGF pathway has
been directly demonstrated by anti-VEGF monoclonal
antibodies, which are active against a variety of human
tumors [11] and ischemic retinal disease [12].
VEGF is a homodimeric cytokine that is expressed in at
least four splice-variant forms of 121–206 residues [10].
Vascular endothelial cells express at least two high-affin-
ity receptors for VEGF: VEGFR1 (also referred to in the
literature as Flt-1) and VEGFR2 (also referred to as
KDR). Another related receptor, VEGFR3/Flt-4, binds the
VEGF-like growth factor, VEGF-C, believed to function in
lymphogenesis [13]. These VEGFRs are receptor tyrosine
kinases each comprised of an extracellular domain that
binds VEGF and contains seven immunoglobulin-like
segments, a short membrane-spanning region, and a cyto-
solic domain possessing tyrosine-kinase activity. The kinase
domain directly follows the extracellular and juxtamem-
brane regions and is itself followed by another domain
(referred to here as the post-kinase domain), which may
function in binding of other proteins for signal transduction.
VEGFR1 and VEGFR2 appear to have different signaling
pathways and functions, with VEGFR2 being of primary
importance in mitosis of endothelial cells [14–16].
On the basis of sequence homology and overall domain
structure, VEGFRs belong to the platelet-derived growth
factor receptor family (PDGFR), which also includes
PDGFRα, PDGFRβ, the stem cell growth factor receptor
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(c-kit), and the colony stimulating factor-1 receptor
(CSF-1R; also referred to as c-fms) [17]. Compared to
other protein kinases, members of this family contain an
insert of approximately 65–97 residues, termed the kinase
insert domain (KID), within the kinase domain. Deletion
or mutation of the KID from PDGFα, PDGFβ, ckit, and
CSF-1R has indicated that this domain is not necessary for
intrinsic kinase activity but that it is important for the
binding of other proteins involved in signal transduction
via autophosphorylation of KID tyrosine residues [18–24].
Although the signaling pathways and the specific role of
the KID are still not fully determined for VEGFRs, the
VEGFR2 KID does contain two tyrosines that have been
shown to be autophosphorylation sites [25].
Since the determination of the first cyclic-AMP-depen-
dent protein kinase (cAPK) structure [26] a variety of
protein kinase structures have been reported [27]. Among
the receptor protein tyrosine kinases (RPTKs), structures
of the kinase domain of the insulin receptor (IRK) [28,29]
and the fibroblast growth factor receptor 1 (FGFR1) [30,31]
have been determined. We report here the generation,
kinetic characterization, and structure determination of a
modified kinase domain of VEGFR2 containing 18 residues
of the 68-residue KID. This 2.4 Å crystal structure of the
phosphorylated VEGFR2 catalytic domain is the first
reported structure of a kinase domain of the PDGFR
family. This structure provides insights into the orienta-
tion of the KID domain of VEGFR2, which may be rele-
vant to other PDGFR family members. Furthermore, as
inhibition of VEGFR2 kinase has broad clinical potential,
this structure provides a three-dimensional description of
the target for structure-based design of small molecule
VEGFR2 inhibitors as therapeutic agents. 
Results and discussion
Kinetic analysis
The tyrosine kinase domain of human VEGFR2 lacking 50
central residues of the 68 residues of the KID was expressed
in a baculovirus/insect cell system. Of the 1356 residues of
full-length VEGFR2, this protein construct (VEGFR2∆50)
contains residues 806–939 and 990–1171 of the cytosolic
domain (Figure 1). In addition to the 50-residue deletion,
VEGFR2∆50 also contains one point mutation (E990V)
within the KID relative to wild-type VEGFR2.
Purified VEGFR2∆50 was found to efficiently catalyze
its autophosphorylation as well as phosphorylation of a
poly(E4Y) exogenous substrate. The kinetic methods and
analysis reported here are very similar to those previously
reported in detail for another VEGFR2 kinase domain
protein construct [32].
Using a spectrophotometric assay kinetic constants were
determined for both native, nonphosphorylated and auto-
phosphorylated VEGFR2∆50 (VEGFR2∆50P) (Table 1).
Kinetic characterization of the native nonphosphorylated
protein was possible because, under the low protein concen-
trations used in the activity assays, no autophosphorylation
of the protein was detected. Quantitation of the ATPase
activity and the phosphotransferase activity indicated that
the two reactions were tightly coupled. No ATPase activity
was observed in the absence of a peptide substrate. 
Since phosphotyrosines are considered high-energy inter-
mediates, the tyrosine-kinase reaction should, in princi-
ple, be reversible. In fact, the enzyme catalyses genera-
tion of ATP from ADP and phosphorylated poly(E4Y)
[p-poly(E4Y)] in the presence of Mg2+. Although capable
of catalyzing the reverse reaction, VEGFR2∆50 clearly
exhibits a commitment to forward reaction as evidenced
by higher kcat for the forward direction relative to that for
the reverse direction: 13.0 and 0.13 s–1, respectively, for
VEGFR2∆50P (Table 1).
It is interesting to note that for both nonphosphorylated
and phosphorylated VEGFR2∆50 the KM(MgADP) is less
than KM(MgATP) and KM(p-polyE4Y) is less than KM(polyE4Y).
However, the relative differences in these Km values are
much smaller than the relative increase in kcat values
between the forward and reverse reactions such that the
kcat/KM values are larger in the forward direction (Table 1).
Comparison of the kinetic constants for VEGFR2∆50 with
those for a VEGFR2 kinase domain containing the entire
KID (cchVEGFR2) [32] shows that the 50-residue KID
deletion in VEGFR2∆50 does not have a significant
impact on in vitro catalytic activity. For example, kcat for
VEGFR2∆50P and phosphorylated cchVEGFR2 in the
forward direction were 13 and 12 s–1,, respectively. Simi-
larly, KM(MgATP) for VEGFR2∆50P and phosphorylated
cchVEGFR2 were 150 and 153 mM, respectively.
Structure determination
The VEGFR2 KID sequence is hydrophilic and highly
charged, containing six lysine, five arginine, eight glutamic
acid, and five aspartic acid residues (Figure 1). Initially,
several protein constructs containing the VEGFR2 cat-
alytic domain with the entire KID were generated (unpub-
lished results). After exhaustive attempts to crystallize
these protein constructs failed to yield even marginal crys-
tals, the VEGFR2∆50 construct was created to test the
idea that the highly charged KID was interfering with
crystallization. As determined by dynamic light scattering
this VEGFR2∆50 construct, which eliminated 14 charged
residues, exhibited markedly more stability and less mul-
timeric aggregation at various temperatures and protein
concentrations than protein constructs containing the entire
KID (data not shown).
For crystallization, purified VEGFR2∆50 was autophospho-
rylated in vitro by incubation with MgATP. Matrix-assisted
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laser desorption ionization (MALDI) and nanoelectro-
spray ionization (NanoESI) mass spectrometry analysis of
full-length phosphorylated VEGFR2∆50 (VEGFR2∆50P)
protein and tryptic-digestion peptides indicates phosphory-
lation of Y1059. Crystals diffracting to 2.2 Å were obtained
of VEGFR2∆50P in an unliganded state. The crystals
belong to the orthorhombic space group P212121, with one
VEGFR2∆50P molecule in the asymmetric unit.
To check that the protein had not dephosphorylated prior to
or during the crystallization process an anti-phosphotyrosine
western blot analysis of dissolved crystals was performed
(Figure 2). In this analysis samples were run of native non-
phosphorylated VEGFR2∆50, VEGFR2∆50P taken at two
time points during the autophosphorylation reaction, and
dissolved crystals. As Figure 2 shows, nonphosphorylated
VEGFR2∆50 did not appreciably bind to the anti-phos-
photyrosine antibodies, whereas the autophosphorylated
VEGFR2∆50P and dissolved crystals showed a strong inter-
action. That the crystals contain phosphorylated protein is
also implied by our observation that nonphosphorylated
VEGFR2∆50 did not crystallize under the crystallization
conditions reported here for VEGFR2∆50P.
Initial crystallographic phases were determined by mol-
ecular replacement using the structure of the unphospho-
rylated kinase domain of FGFR1 [30] as a search model.
The correctness of the molecular replacement solution
was cross-checked by calculating a difference Fourier with
a gold cyanide derivative. The derivative data, however,
were not included for phase calculations of electron-
density maps used to build the model. The structure has
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Figure 1
Sequence alignment of the kinase domain of
VEGFR2 and other RPTKs. Secondary
structural elements of VEGFR2∆50P are
indicated: α helices are designated as αC–αI,
β strands are designated as β1–β8, and loops
are indicated by curves. The site of the 50-
residue deletion in VEGFR2∆50 is indicated
by |. The site of the E990V mutation in
VEGFR2∆50 is denoted by an *. Sequences
are from VEGFR2 (reported here); FGFR1
(SWISSPROT accession number P11362);
IRK (EMBL database number A18657;
numbering as in [30]); VEGFR1
(SWISSPROT number P17948); PDGFRα
(SWISSPROT number P17948).
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Structure
been refined to an R factor of 20.2% for 8–2.4 Å data
(Fo > 2σ). VEGFR2∆50P residues for which backbone
atoms were not modeled due to disorder include the N-ter-
minal residues 806–819, residues 990–997 of the KID,
residues 1048–1063 of the activation loop, and residues
1169–1171 of the C terminus. Structure-determination sta-
tistics are included in Table 2. 
Overall kinase fold
Analogous to previously reported structures of both serine/
threonine and tyrosine protein kinases, VEGFR2∆50P is
folded into two lobes, with catalysis of phosphotransfer
taking place in a cleft between the two lobes (reviewed in
[27,33]). A Cα trace of the VEGFR2∆50P structure is shown
in Figure 3a. Kinase secondary structural elements are desig-
nated (Figure 1) according to the convention originally given
for cAPK [26]. The N-terminal lobe (approximately residues
820–920) folds into a twisted β sheet with one α helix (αC).
The β structure comprises five antiparallel strands (β1–β5),
three of which (β1–β3) are highly curved and curl over the
other two strands (β4–β5). The larger C-terminal domain
(approximately residues 921–1168) contains two antiparallel
β strands (β7–β8), which lie at the top of the C-terminal
domain adjacent to the N-terminal β sheet. Seven α
helices (αD, αE, αE-F, αF, αG, αH, αI) form the remain-
ing core of the C-terminal domain. Like other kinases,
VEGFR2∆50P also contains functionally important loop
regions: the glycine-rich nucleotide binding loop (residues
841–846), the catalytic loop (residues 1026–1033) and the
activation loop (residues 1046–1075; Figures 1 and 3a). 
Of the reported kinase structures, the VEGFR2∆50P struc-
ture resembles most closely that of the catalytic domain
of FGFR1 [30] with which it shares approximately 55%
sequence identity (Figure 1). As the two molecules in the
crystallographic asymmetric unit of the FGFR1 structure
solution are very similar, comparisons to VEGFR2∆50P
will primarily be described only for the FGFR1 molecule
A. Least-squares superposition of 82 Cα positions of strands
(β1–β5) of the N-terminal lobe or 152 Cα positions of
helices (αD, αE, αF, αG, αH, αI) of the C-terminal lobe
between FGFR1 and VEGFR2∆50P result in respective
root mean square  deviation (rmsd) values of 0.40 Å and
0.52 Å. A relative rotation of approximately 5° between the
two lobes results in the interlobe cleft of VEGFR2∆50P
being slightly larger and more open. Measurement of dis-
tances between equivalent Cα atoms (K523 and R675 of
FGFR1, S877 and R1080 of VEGFR2∆50P) at the ends of
the cleft reveal that this distance is 25.3 Å in VEGFR2∆50P
in comparison with 23.2 Å in FGFR1. This is, however, a
minor difference in comparison with much larger relative
lobe rotations observed among kinase structures in various
complexes and phosphorylation states [27]. For example,
the interlobe orientation seen here for VEGFR2∆50P is in
an approximately 20° more open conformation than that
seen in the ternary complex structure of the phosphory-
lated kinase domain of IRK bound to the ATP analog,
adenylyl imidodiphosphate (AMP-PNP) and a peptide sub-
strate [29] (Figure 3c). 
Although the β-strand positions of the N-terminal lobe
agree well between VEGFR2∆50P and FGFR1, the struc-
tures do diverge significantly at the N-terminal residues
preceeding the first conserved region, which starts at residue
W827 (Figure 3a and 3b). The first 14 residues (M806–
E819) of VEGFR2∆50P are completely disordered and the
next seven residues (L820–R826) form an extended-loop
structure. It is likely that residues 806–819 do not form
part of the active kinase region but are instead part of, or
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Table 1
Kinetic constants of VEGFR2∆50
Native VEGFR2∆50 Phosphorylated VEGFR2∆50
Substrate KM (mM) kcat(s–1) kcat/KM (s–1M–1) KM (mM) kcat (s–1) kcat/KM (s–1M–1)
Forward reaction
MgATP 0.597 5.5 9.2 × 103 0.153 13.3 87 × 103
poly(E4Y) 9.4 5.8 × 102 2.1 63 × 102
Mg2+ 31.0 1.8 × 102 6.8 20 × 102
Reverse reaction
MgADP 0.127 0.1 7.9 × 102 0.056 0.13 23 × 102
p-poly(E4Y) 1.3 7.7 × 101 1.0 13 × 101
Figure 2
Phosphorylation state of VEGFR2∆50 crystals. A cross section of an
antiphosphotyrosine western blot is shown. Regions of the blot not
shown did not contain visible bands. Lane 2, purified VEGFR2∆50;
Lane 4, purified VEGFR2∆50 after 20 min of autophosphorylation;
Lane 6, purified VEGFR2∆50 after 40 min of autophosphorylation;
Lane 10, dissolved crystals.
are adjacent to, the juxtamembrane region of VEGFR2.
Residues 820–826 do seem to be part of the kinase domain
as analogous residues are also ordered in the structures of
FGFR1, IRK, and the non-receptor tyrosine kinase Lck
[34]. Other differences between the VEGFR2∆50P struc-
ture and other kinase structures occur at the KID and the
activation loop (discussed below).
Catalytic loop and ATP-binding site
In protein kinases, the loop between αE and β7 has been
termed the catalytic loop as it contains an invariant aspartic
acid residue (D1028) that is essential for catalysis of the
phosphotransfer reaction [27]. This aspartic acid is part of a
stretch of residues (H1026–N1033) whose sequence HRD-
LAARN (single-letter amino acid code) is highly conserved
among protein tyrosine kinases. In VEGFR2∆50P the back-
bone position and most sidechain positions of this loop are
similar to those in the unliganded FGFR1 and ternary
phosphorylated IRK (IRKP) complex structures. As seen in
these previous structures, the sidechain carboxylate of the
catalytic loop aspartic acid (D1028) is hydrogen-bonded
to the sidechains of the conserved arginine (R1032) and
asparagine (N1033; Figure 4).
The ATP-binding site of protein kinases lies at the cleft
between the N- and C-terminal lobes (Figure 3c). For
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Table 2
VEGFR2∆50P structure determination statistics
Data set Native (3) Native (1) Native (2) KAu(CN)2
Data resolution (Å) 15–2.2 20–2.9 15–2.4 15–3.1
Rsym*† (%) 5.2 (19.6) 8.4 (26.6) 7.0 (21.9) 7.1 (19.5)
Completeness (%) 93.0 (81.0) 97.5 (98.4) 98.8 (98.8) 96.5 (95.0)
Temperature (oC) –186 room (~21) 4 4
Unit cell a (Å) 95.41 97.10 98.52 97.71
Unit cell b (Å) 96.04 96.94 96.50 96.97
Unit cell c (Å) 38.22 38.63 38.56 38.52
Refinement resolution (Å) 8–2.4 — — —
Refined R‡§ (%) 20.2 — — —
Rfree¶ (%) 27.3
*Rsym = 100 × ΣhklΣi|Ii (hkl)–<I(hkl)>| / ΣhklΣiIi (hkl). †Value in
parentheses is for highest resolution shell: Native (3), 2.28–2.20;
Native (1), 3.02–2.90; Native (2), 2.49–2.40; KAu(CN)2, 3.21–3.10.
‡R = 100 × Σhkl| |Fo(hkl)|–|Fc (hkl)| | /Σhkl |Fo (hkl)| where Fo and Fc are
the observed and calculated structure factors, respectively (Fo > 2σ).
§Model includes 275 protein residues and 182 water molecules.
¶Calculated using a test set of 7% of the Native (3) data and
subjecting the final refined model to simulated annealing and
positional refinement with this test set not included in the
minimization calculations.
Figure 3
Overall fold of VEGFR2∆50P, FGFR1, and
IRKP. Backbone representation of structures
of the kinase domains of (a) VEGFR2
(VEGFR2∆50P), (b) FGFR1 ([30], molecule
A of Protein Data Bank [PDB] entry 1FGK),
and (c) IRKP ([29], PDB entry 1IR3). The
views shown in (a), (b), and (c) are identical
views generated from superpositions of the
C-terminal domains. The positions of the
termini are denoted by N and C. In (a) β
strands are designated as β and α helices
are indicated by α. The nucleotide-binding
loop (orange), KID (purple), and activation
loop (yellow) are highlighted. In (c) the bound
AMP-PNP is shown in green and the peptide
substrate is shown in red. The figure was
prepared with the program INSIGHT II [53].
VEGFR2∆50P, the residues forming this site consist pri-
marily of residues E917–N923 that join the two lobes, and
residues L840–I849 that include parts of β1, β2 and the
glycine-rich loop of G841–G846. The glycine-rich loop,
also referred to as the nucleotide binding loop, is a flexible
segment whose position differs among kinase structures in
various activated and liganded states. In VEGFR2∆50P
this loop is fairly well ordered and all atoms could be
modeled, with the exception of the sidechains of R842
and F845. The relative position and conformation of this
loop is similar to that observed in the unliganded FGFR1
structure. However, this position is markedly different from
that in the IRKP ternary complex structure in which the
approximately 20° relative rotation of the N- and C-termi-
nal lobes results in the glycine-rich loop being 5 Å closer
to the C-terminal lobe than in VEGFR2∆50P.
In reported kinase structures with bound ATP or an ATP
analog, the adenine ring makes two conserved hydrogen
bonds with the protein backbone. In the structure of
FGFR1 with adenylyl methylenediphosphate (AMP-PCP)
bound [30], these hydrogen bonds are between the adenine
NH2 and the backbone C=O of E562 (E917 VEGFR2∆50P)
and between the adenine N1 and the backbone NH of
A546 (C919 VEGFR2∆50P). Although the structure pre-
sented here does not contain a bound nucleotide, the sim-
ilarities in the positions of these backbone atoms to those
in FGFR1 indicate that these hydrogen bonds would be
formed in a VEGFR2∆50P–ATP complex and therefore the
adenine is expected to bind in a similar position (Figure 5). 
Variation in the ATP-binding sites of kinases involved
in disease is of considerable importance in the design of
selective ATP-competitive inhibitors as therapeutics. A
comparison of the ATP-binding sites of FGFR1 and
VEGFR2∆50P reveals that while the overall architecture
of the site is conserved, several sequence differences result
in differences in the shape of the accessible area for ligand
binding. Specific sequence differences between FGFR1
and VEGFR2 in this site include V899 (I545 FGFR1),
F918 (Y563 FGFR1), C919 (A564 FGFR1), and C1045
(A640 FGFR1; Figure 5). Similarly, comparison to the
ternary IRKP complex structure reveals variation in the
adenine site at V916 (M1076 IRK), F918 (L1078), C919
(M1079 IRK), L1035 (M1139 IRK), and C1045 (G1149
IRK). Even greater sequence and structural variation in the
adenine site is seen when the VEGFR2∆50P structure is
compared to serine/threonine-kinase structures, suggesting
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Figure 5
Nucleotide-binding site of VEGFR2∆50P and
FGFR1. Stereoview showing the Cα trace and
some sidechains of a superposition of the
nucleotide-binding sites of the VEGFR2∆50P
and the FGFR1–AMP-PCP complex ([30];
molecule B) structures. The superposition was
performed using Cα positions of helices (D, E,
F, G, H, and I) of the C-terminal lobes. Carbon
atoms of VEGFR2∆50P are shown in yellow
and carbon atoms of FGFR1 are shown in
purple. The coloring for other protein atoms is:
oxygen (red), nitrogen (blue), and sulfur (green).
The AMP-PCP in the FGFR1 structure is
depicted in orange. Labels correspond to
VEGFR2∆50P residues. The figure was
created with the program Xfit [50].
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Figure 4
Catalytic site of VEGFR2∆50P and IRKP.
Cross section of the catalytic site of (a)
VEGFR2∆50P and (b) IRKP [29] structures.
Protein Cα ribbon representations are shown in
light blue. In (b) the Cα ribbon representation
of the bound peptide substrate is shown in
orange. Specific atoms are colored by element
type: carbon (green), oxygen (red), nitrogen
(blue), phosphorous (purple),and magnesium
ions (yellow). (a) includes only protein atoms.
(b) includes protein atoms, peptide atoms,
AMP-PNP atoms, and Mg2+ ions. The figure
was generated using INSIGHT II [53].
that these differences could be exploited in the design of
selective ATP-competitive inhibitors. 
Activation loop
Protein kinases contain a large flexible loop, referred to as
the activation loop (A loop), whose conformation is postu-
lated to regulate kinase activity (Figure 3). In many kinases
the conformation of the A loop is controlled by the phos-
phorylation of specific A-loop residues [27]. The loop can
be generally defined as beginning with the conserved
residues DFG and ending at the conserved APE sequence
[27]. In VEGFR2 this segment corresponds to D1046–
E1075 and contains two tyrosines (Y1054 and Y1059). Both
Y1054 and Y1059 were found to be autophosphorylation
sites when the cytosolic domain of VEGFR2 was expressed
in Escherichia coli [25]. Using the in vitro autophosphoryla-
tion protocol described here for VEGFR2∆50, a stable
phosphorylation site is indicated at Y1059; however, no evi-
dence of phosphorylation of Y1054 was detected.
In the VEGFR2∆50P structure presented here, the A loop
appears quite mobile and interpretable electron density
was not present for most of the central portion of the loop
(G1048–G1063). This disorder is consistent with mobility
of the A loop deduced from other kinase structures. For
example, of the two molecules in the asymmetric unit of
the unphosphorylated FGFR1 kinase structure, the center
of the A loop has relatively high temperature factors in
molecule A and is completely disordered in molecule B.
Although residues 1048–1063 could not be modeled in
VEGFR2∆50P, unambiguous electron density was present
for residues D1064–E1075, clearly indicating that these
residues adopt a conformation similar to that observed in
the unphosphorylated FGFR1 structure. The segment of
D1064–P1068 has an extended structure that lies adjacent
to the catalytic residues D1028 and R1032 (Figure 4a).
Comparison with the structure of the MgAMP-PNP–
peptide–IRKP complex indicates that the position of
R1066–P1068 in this VEGFR2∆50P structure is inhibitory
to substrate binding. P1066 occupies the equivalent space
allocated to the tyrosine sidechain of the peptide substrate
in the ternary IRK3P complex structure. The conformation
of residues L1069–E1075 is similar to that in the ternary
IRKP complex structure. However, there is a complete
directional change at P1068 (P1172 IRK) between the two
structures. In the IRK structure, residues N-terminal to
this proline are directed toward αEF, whereas in
VEGFR2∆50P they are directed toward αD on the oppo-
site side of the protein (Figures 3 and 4).
It is somewhat surprising that despite the phosphorylation
of Y1059 prior to crystallization, the conformation seen here
for residues D1064–P1068 is similar to the inhibitory con-
formation observed for analogous residues in the unphos-
phorylated FGFR1 structure. Y1059 in VEGFR2∆50 corre-
sponds to a relatively conserved phosphorylation site among
protein tyrosine kinases. In the ternary IRKP complex
structure and the phosphorylated Lck structure [34], the
tyrosine at this position (Y1163 IRK, Y394 Lck) is phos-
phorylated and the A loop has a non-inhibitory conforma-
tion similar to that observed in a phosphorylated cAPK
ternary complex structure [35]. The interactions the phos-
phate group at this position makes with other protein
residues are believed to help stabilize an A-loop confor-
mation that allows substrate and ATP binding [27,29].
However, as the VEGFR2∆50P structure described here
does not exhibit a similar open A-loop conformation but
rather has an inhibitory conformation with much of the
loop disordered, it is possible that the monophosphory-
lated A  loop of VEGFR2∆50P exists in a dynamic equilib-
rium involving several conformations and that the confor-
mation observed here is the one most favored in this
crystal environment.
Kinase insert domain
The kinase insert domain occurs in the kinase C-terminal
lobe and connects helices αD and αE. In VEGFR2 this
region corresponds to a 68-residue stretch from N933 to
L1000 (Figure 1). The lack of effect on intrinsic kinase
activity (noted above) of deletion of residues T940–E989
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Figure 6
Electron-density map of the kinase insert
domain area of VEGFR2∆50P. Stereoview of
a 2Fo–Fc map computed at 2.4 Å and
contoured at 1.2σ, and superimposed with
the refined model. Carbon atoms are yellow,
oxygen atoms red, and nitrogen atoms are
blue. Water molecules are depicted as red
crosses. The figure was created with Xfit [50].
is perhaps not surprising, as the ends of the KID domain
are relatively far away (approximately 35–40 Å) from the
catalytic site and are on the opposite side of the protein
from the position of the activation loop (Figure 3). These
results agree with those for the CSF-1R kinase in which
deletion of 58 of the 64 residues of the CSF-1R KID
only decreased its ability to phosphorylate a peptide sub-
strate by 10% [18]. Deletion of the entire 98 KID residues
of βPDGFR, however, resulted in an 80% decrease in
kinase activity towards a peptide substrate [36]. Consid-
ered together, these results suggest that the majority of
the KID is not required for catalysis but that a small number
of residues must be present to form a linker between αD
and αE to maintain a competent kinase structure.
In the VEGFR2∆50P structure, following αD, residues
N933–P937 form a loose turn and an extended strand
whose ends are roughly perpendicular to the axes of αD
and αI at the C terminus. In difference Fourier maps the
electron density is strong and clear for residues N933–P937
and becomes weak for Y938 and K939 (sidechains of Y938
and K939 are not modeled; Figure 6). The 50-residue
deletion in VEGFR2∆50 directly follows K939 so that the
residue immediately C-terminal to K939 is V990, main-
taining the residue numbering in full-length VEGFR2.
Residues V990–K997 are disordered and interpretable
electron density begins again at D998. Residues D998–
T1001 then form a short strand that joins αE at residue
L1002 (Figures 6 and 7).
An interesting feature of these two strands at the N- and
C-terminal ends of the KID is that they form a pseudo
two-stranded parallel β-sheet structure that is quite differ-
ent from the conformations seen in this region of other
kinase structures. The two ends of the KID thus make a
variety of interactions that may help to stabilize the overall
conformation and position of this domain in VEGFR2. The
sidechain of K931 makes an ionic interaction with the
sidechain of E934 and also makes a hydrogen bond with the
backbone carbonyl of D998 (Figure 7). Hydrogen-bonding
interactions between the strands include E934 backbone
C=O to L1000 NH, V936 NH to L1000 C=O, and P937
C=O to L1002 NH. In addition to these polar interactions,
the sidechains of F935, P937, and L1000 are involved in
extensive hydrophobic contacts. The sidechain of F935 is
nestled in a hydrophobic pocket formed by the sidechains
of L928, P937, L1000, L1002, L1005, L1101, and Y1130
(Figures 6 and 7). The L1000 sidechain also packs against
the sidechains of Y927, K931, H1004, and Y1008. 
The length, composition, and structure of the connecting
region between αD and αE varies considerably among
kinases. For brevity, only comparisons to the IRK and
FGFR1 receptor tyrosine kinase structures will be described
here. In IRK this connection stretches twelve residues,
of which five are proline, from P1093 to P1104. This
proline-rich segment is ordered and exhibits similar loop-
like conformations in the unphosphorylated apoenzyme
structure [28] and in the phosphorylated ternary complex
structure [29]. The most significant divergence in the KID
position in IRK and VEGFR2∆50P begins immediately fol-
lowing αD at N933 (P1093 IRK). In IRK, residues P1093–
G1100 form a loop that folds towards the N-terminal domain.
By contrast, the path taken by N933–K939 in VEGFR2∆50P
is towards the C-terminal helix αI (Figure 3a). 
In FGFR1 the connection between αD and αE is 18
residues long (P578–L595) and shares little sequence
homology with VEGFR2 or IRK. In FGFR1 this region
is apparently quite mobile because, for the two mol-
ecules in the crystallographic asymmetric unit of the
FGFR1 structure, residues 580–591 are disordered in
molecule A and residues 578–593 are disordered in mol-
ecule B [30]. Although most of this segment is disor-
dered in FGFR1, the ordered ends follow a path more
similar to IRK than to VEGFR2∆50P.
Sequence comparisons with other members of the PDGFR
family suggest that some of these kinases may have confor-
mations for the beginning and end residues of the KID
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Figure 7
Stereo cross section showing the ordered
residues of the KID of VEGFR2∆50P.
Carbon atoms are yellow, oxygen atoms are
red, nitrogen atoms are blue, and sulfur
atoms are green. The view is rotated roughly
180° from that of Figure 6. The figure was
created with Xfit [50].
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similar to those seen here for VEGFR2∆50P. In particular,
there is significant sequence homology in the first four
KID residues (N933–V936) that make the turn towards the
C terminus. Of these residues, a phenylanine at the posi-
tion of F935, which makes extensive hydrophobic interac-
tions, may be particularly important for structural integrity
as a phenylalanine occurs at this position in sequence align-
ments with VEGFR1, VEGFR3, αPDGFR, βPDGFR, and
ckit [37–40].
Biological implications
The crystal structure and kinetic characterization of a
protein construct (VEGFR2∆50) of vascular endothelial
growth factor receptor 2 (VEGFR2), containing the
kinase core and 18 of the 68 residues of the kinase insert
domain (KID), provide several biological insights. The
high similarity in overall fold and catalytic-residue posi-
tions to the fibroblast growth factor receptor 1 (FGFR1)
and insulin receptor kinase (IRK) kinase domain struc-
tures suggests that the catalytic mechanism of VEGFR2,
and other platelet-derived growth factor receptor PDGFR-
family members, is consistent with other tyrosine kinases.
Tyr1059, of the VEGFR2 kinase activation loop, was
confirmed to be an autophosphorylation site. The activa-
tion loop is predicted to exist in a dynamic equilibrium of
several conformations, one of which is similar to a con-
formation observed in FGFR1 and is inhibitory to sub-
strate binding. 
As deletion of the 50 central residues of the KID did not
affect autophosphorylation or kinase activity on an exoge-
nous substrate, this domain does not seem to have a
direct function in the phosphotransfer reaction. Although
not directly involved in catalysis, evidence suggests that
the KID functions in signal transduction as a binding
site for cellular proteins. The VEGFR2 KID contains
three tyrosines (Y938, Y951, and Y996) of which Y951
and Y996 have previously been shown to be autophos-
phorylation sites. The determination of these autophos-
phorylation sites as binding sites for other proteins has
yet to be reported for VEGFR2; however, phosphatidyl
inositol 3 kinase, Grb2, and SHP-2 have been to shown
to bind to phosphotyrosines in the KID of other PDGFR
family members [41].
In the structure reported here, the residues forming the
two ends of the VEGFR2 KID interact with each other to
form a pseudo-β substructure not observed in previous
protein kinase structures. This substructure is stabilized
by a large number of interactions and is expected to also
occur when the entire KID is present. The close proximity
of this pseudo-β substructure to the post-kinase domain
implies that the KID and post-kinase domains pack near
to each other in full-length VEGFR2 and perhaps in other
PDGFR family members. In this case, the pseudo-β struc-
tural element may serve to orient the KID to pack near to
the post-kinase domain. As both the KID and the post-
kinase domains of these receptor protein tyrosine kinases
(RPTKs) are believed to be involved in the binding of
other proteins, it is possible that having the KID and post-
kinase domains in near proximity may facilitate formation
of multimeric complexes for signal transduction. 
Materials and methods
Cloning
The coding sequence [42] for the cytoplasmic domain of the VEGFR2
was amplified by the polymerase chain reaction (PCR) [43] from a
human aorta cDNA pool (Clontech, Palo Alto, CA). Two overlapping
sequences were amplified independently: Vcyt (residues M806–V1356),
which represented the entire cytoplasmic domain, and Vcat (residues
C817M–G1191), with boundaries based upon a primary amino acid
sequence alignment with the insulin receptor kinase catalytic domain
[44]. The PCR oligonucleotide primer sequences for Vcyt were; Vcyt5:
5′-CAGCATATGGATCCAGATGAACTCCCATTGG-3′ and Vcyt: 5′-
GCGGTCGACTTAAACAGGAGGAGAGCTCAGTGTG-3′. The PCR
oligonucleotide primer sequences for the Vcat were; Vcat5 5′-GCA-
CATATGGAACGACTGCCTTATGATGCCAGC-3′ and Vcat3: 5′-CC-
TGTCGACTTATCCAGAATCCTCTTCCATGCTCAAAG-3′. The amplified
DNA was digested with the restriction enzymes NdeI and SalI, ligated
into the E. coli plasmid pET24a (Novagen Madison, WI), and the
sequence verified. When compared to the original sequence in
GENBANK, accession number 346345, two nucleotide differences
were noted that resulted in amino acid changes (Glu848→Val and
Asn835→Lys) in both Vcyt and Vcat. Our sequence agrees with
subsequent VEGFR2 GENBANK submissions (accession numbers
2655412 and 3132833). 
Mutations were introduced by oligonucleotide site-directed mutagene-
sis [45] using the Muta-Gene in vitro Mutagenesis Kit from Bio-Rad
(Hercules, CA). The Vcat DNA fragment was subcloned from the
pET24a vector using an NdeI–XhoI digest into the vector pMGH4
[46,47] and this vector was used to generate the single-stranded
DNA (ssDNA) uracil-containing template (minus strand) in E. coli
strain CJ236 supplied in the kit. An oligonucleotide (5′-GCTCAGCA-
GGATTGATAAGACTACATTGTTC-3′) was designed to create a con-
struct, Vcat(∆G1172–G1191), which truncated the C terminus to
residue D1171. Another oligonucleotide (5′-GAATTTGTCCCCTACAA-
GGAAGCTCCTGAAGATCTG-3′) was designed to delete the central
50 residues (residues T940–E989) of the KID, on the basis of a
sequence alignment with FGFR1 [30]. Sequence analysis detected an
inadvertent Glu990→Val mutation. All DNA modification and restric-
tion enzymes were purchased from New England Biolabs and oligonu-
cleotides were purchased from Genosys Biotechnology. 
The DNA encoding the VEGFR2∆50 protein construct was made in
several steps to combine the necessary mutations into the baculovirus
expression vector pAcSG2 (Pharmingen, San Diego, CA). Step 1: the
coding region for Vcyt was subcloned from the pET24a vector into the
NcoI–KpnI sites of vector pAcSG2. Step 2: a 2358 base pair (bp)
ScaI–BglII DNA fragment from plasmid pMGH4–Vcat(∆T940–E989,
E990V) was ligated to a 1695bp BglII–ScaI DNA fragment from
pMGH4–Vcat(∆G1172–G1191) creating a pMGH4–Vcat(∆T940–E989,
E990V, ∆G1172–G1191) vector. Step 3: a 913bp BstEII–EagI DNA
fragment, a pMGH4–Vcat(∆T940–E989, E990V, ∆G1172–G1191),
was ligated to a 3290bp EagI–BstEII DNA fragment from pAcSG2–Vcyt,
creating pAcSG2–Vcyt(∆T940–E989, E990V, ∆G1172–G1191). This
final DNA construct was sequenced, verified through the entire coding
region and it was confirmed to contain only these known mutations from
the wild-type sequence (Figure 1).
The pAcSG2–Vcyt(∆T940–E989, E990V, ∆G1172–G1191) DNA,
expressing the VEGFR2∆50 protein, was transfected into Spodoptera
frugiperda (Sf9) cells with linearized baculovirus DNA according to the
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protocol of the manufacturer (Pharmingen, San Diego, CA). Single
plaques were isolated from this transfection and high-titer stocks gener-
ated. All stocks were examined by isolation of baculoviral DNA and PCR
amplification of the insert using the polyhedrin forward and reverse
primers (Invitrogen). Sf21 cells were infected at 1–1.5 million cells/ml at
a multiplicity of infection of 5 for 72 h and harvested by centrifugation.
Protein purification
Cell pellets were lysed by dounce homogenization and sonication in
20 mM Tris pH 8.0, 20 mM NaCl, 5 mM dithiothreitol (DTT), and 5%
(v/v) glycerol. The lysate was centrifuged for 50 minutes at 35,000 rpm
in a Ti45 rotor. The soluble fraction was loaded onto a 40 ml Q-30
anion-exchange column (Pharmacia, Piscataway, NJ) and eluted with a
20–600 mM NaCl gradient in 20 mM Tris pH 8.0, 5 mM DTT, and 5%
(v/v) glycerol over 20 column volumes. VEGFR2∆50 was pooled by
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
analysis and by the presence of kinase activity as measured against
gastrin peptide substrate (Boehringer Mannheim, Indianapolis, IN).
Pooled material was loaded onto a 40 ml hydroxyapatite (Bio-Rad, Her-
cules, CA) column and washed extensively with 20 mM Tris pH 8.0,
50 mM NaCl, 5 mM DTT, and 5% glycerol. Protein was eluted using a
500 ml linear gradient from 0–50 mM potassium phosphate pH 8.0,
50 mM NaCl, 5 mM DTT, and 5% glycerol. VEGFR2∆50 was pooled
by SDS–PAGE analysis and by the presence of kinase activity as mea-
sured against the gastrin peptide. Material from this column was then
diluted 1:1 with 20 mM Tris pH 8.0, 20 mM NaCl, 5 mM DTT, and 5%
glycerol and loaded onto an 8 ml Q-15 anion-exchange column
(Pharmacia). Protein was eluted using a 180 ml linear NaCl gradient
(20–175 mM) in 20 mM Tris pH 8.0, 5 mM DTT, and 5% glycerol.
VEGFR2∆50 was pooled as described above. (NH4)2SO4 (4M) was
added to the pool to a final concentration of 0.6 M and the pooled
material was loaded onto a 10 ml HP-phenyl sepharose column (Phar-
macia). VEGFR2∆50 was eluted using a 200 ml linear reverse gradient
from 0.6–0 M (NH4)2SO4 in 20 mM Tris and 5 mM DTT. Purified
VEGFR2∆50 was buffer exchanged into 50 mM Hepes pH 7.5, 10 mM
DTT, 10% glycerol, and 25 mM NaCl over a 500 ml G-25 column (Phar-
macia) and concentrated to 1 mg protein/ml through a 10 kDa cutoff
polysulfone membrane (Millipore, Bedford, MA). Final material was
aliquoted and flash frozen in liquid N2 and stored at –70°C. 
Kinetic assays
Kinetic assays of phosphorylated VEGFR2 were performed with puri-
fied VEGFR2∆50 that was autophosphorylated under the following
conditions: protein (4 mM), ATP (3 mM), MgCl2 (40 mM), DTT (5 mM),
in Hepes (100 mM), 10% glycerol, pH 7.5, at 4°C for 1 h. Analysis of
data was carried out as described in [32].
Coupled spectrophotometric assay for the forward reaction
Tyrosine-kinase assays were monitored using a Beckman DU 650
spectrophotometer. Production of ADP was coupled to oxidation of
NADH using phosphoenolpyruvate (PEP) through the actions of pyru-
vate kinase (PK) and lactic dehydrogenase (LDH). The oxidation of
NADH was monitored by following the decrease in absorbance at
340 nm (ε340 = 6.22 cm–1mM–1). Typical reaction solutions contained
1 mM PEP, 250 mM NADH, 50 units of LDH/ml, 20 units of PK/ml,
5 mM DTT, in 200 mM Hepes, pH 7.5, and indicated concentrations of
poly(E4Y1) (Sigma, St. Louis, MO), ATP and MgCl2. Assays were initi-
ated with either VEGFR2∆50P (40 nM) or VEGFR2∆50 (70 nM). For
nonphosphorylated enzyme, KM(MgATP) was determined by varying the
ATP concentration at fixed concentrations of Mg2+ and poly(E4Y) (60
and 20 mM, respectively). For phosphorylated enzyme, KM(MgATP) was
determined by varying the ATP concentration at fixed concentrations of
Mg2+ and poly(E4Y) (25 and 5 mM, respectively). KM(polyE4Y) for the
nonphosphorylated enzyme was determined by varying the concentra-
tion of poly(E4Y) at fixed concentrations of Mg2+ and ATP (65 and 2 mM,
respectively). KM(polyE4Y) for the phosphorylated enzyme was deter-
mined by varying the concentration of poly(E4Y) at fixed concentrations
of Mg2+ and ATP (25 and 5 mM, respectively). For nonphosphorylated
enzyme, KM(Mg2+) was determined by varying the Mg2+ concentration at
fixed concentrations of ATP and poly(E4Y) (2 and 18 mM, respectively).
For phosphorylated enzyme, KM(Mg2+) was determined by varying the
Mg2+ concentration at fixed concentrations of ATP and poly(E4Y) (1
and 5 mM, respectively). 
Coupled spectrophotometric assay for the reverse reaction
ATP generation was coupled to production of NADH via the action of
hexokinase (HK) and glucose-6-phosphate dehydrogenase (G6PD). In
this assay, HK catalyzes the conversion of ATP to ADP and glucose-6-
phosphate. Glucose-6-phosphate is then oxidized to D-6-phosphoglu-
conopyranose-1,5-lactone by G6PD, with concomitant reduction of NAD
to NADH, which can be monitored at 340 nm. Typical assay solution
contained glucose (10 mM), NAD (40 mM), DTT (5 mM), MgCl2 (4 mM),
HK (15 unit/ml), G6PD (15 units/ml) and indicated concentrations of
ADP and phospho-poly(E4Y). The reactions were initiated with addition
of either VEGFR2∆50P (600–900 nM) or VEGFR2∆50 (950 nM). For
the phosphorylated enzyme, KM(MgADP) was determined by varying the
ADP concentration at fixed concentrations of Mg2+ and p-poly(E4Y) (10
and 8 mM, respectively). For the non-phosphorylated enzyme, KM(MgADP)
was determined by varying the ADP concentration at fixed concentra-
tions of Mg2+ and p-poly(E4Y) (10 and 5 mM, respectively). KM(p-polyE4Y)
for the both the phosphorylated and non-phosphorylated enzyme was
determined by varying the concentration of p-poly(E4Y) at fixed concen-
trations of Mg2+ and ADP (10 and 1 mM, respectively). 
In vitro autophosphorylation for crystallization and mass
spectrometry
Aliquots of frozen VEGFR2∆50 were thawed by immersion in cold H20
and pooled at 4°C. MgCl2 and ATP were added to 26 mM and 4 mM,
respectively. VEGFR2∆50 was incubated at 4°C for 1 h. This material
(VEGFR2∆50P) was then buffer exchanged into a solution of 10 mM
Hepes pH 7.5, 10 mM DTT, and 10 mM NaCl, and was concentrated
using a Centriprep-10 (Millipore) to 5 mg protein/ml.
Mass spectrometry: trypsin digestion
Trypsin digestions of purified VEGFR2∆50 and VEGFR2∆50P were
conducted at 37°C using 0.37 mg/ml protein in 25 mM NH4HCO3 at
pH 7.7 with a reaction volume of 100 µl for two days. 
Mass spectrometry:  MALDI MS
Matrix-assisted laser desorption mass spectrometry (MALDI MS) analy-
ses were performed in a Voyager-Elite, time-of-flight mass spectrome-
ter with delayed extraction (PerSeptive Biosystems, Inc., Framingham,
MA). A volume of 1 µl of digested protein sample was mixed with 1 µl
of matrix (α-cyano-4-hydroxy-cinnamic acid) in a solution of 50% (v/v)
acetonitrile and 0.25% (w/w) trifluoroacetic acid in water. Samples
were irradiated with a nitrogen laser operated at 337 nm. 
Mass spectrometry: nanoESI MS
Nanoelectrospray ionization (NanoESI) MS analyses were performed
on a triple quadrapole mass spectrometer (PE Sciex API III, Alberta,
Canada) modified with a nanoESI source from Protana A/S (Denmark).
The ESI volatage was set at 700 V and the orifice settings were main-
tained at 100 V. A volume (3 µl) of digested protein was mixed with
7 µl of methanol and 0.5 µl formic acid, and then 4 µl of this sample
was injected into the mass spectrometer. Ion scans were used to
obtain the sequence of phosphopeptides.
Crystallization
Purified phosphorylated VEGFR2∆50 was concentrated on average to
5 mg protein/ml using a Centricon-10 centrifugal concentrator. Crystals
were grown by the hanging-drop vapor-diffusion method at 4°C. Drops
containing 2 µl of protein solution and 2 µl of a mother-liquor solution
(100 mM Hepes pH 7.2, 2 M (NH4)2SO4, and 2% (v/v) monomethylether
polyethylene glycol, molecular weight (MW) = 550 kDa) were equili-
brated above a 1 ml reservoir of the mother-liquor solution to which
50 mM β-mercaptoethanol had been added. Crystals appeared after
3–4 days and grew to as large as 0.3 × 0.2 × 0.5 mm over 21 days. 
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Western-blot analysis of crystals
Crystals were removed from the crystallization drops with fiber loops,
washed four times in 5 µl of mother-liquor solution, and dissolved in 25 µl
of a solution containing 50 mM Hepes pH 7.5 and 10% DMSO. The
crystallization sample was run on an SDS polyacrylamide gel along with
control samples of approximately 0.15 µg of purified nonphosphorylated
VEGFR2∆50 and VEGFR2∆50 after 20 min and 40 min of the autophos-
phorylation reaction. Kinase activity in all samples was stopped by bring-
ing the final solution to 25 mM Hepes pH 8.0, 40 mM EDTA pH 8.0,
10% glycerol, and 40 mM NaCl. The western blot was performed using
the ECL blotting kit from Amersham Inc. (Arlington Heights, IL). The
primary antibody solution was a 1:1000 dilution of mouse anti-phospho-
tyrosine mAb PY20 and the secondary antibody was a 1:1500 dilution of
goat anti-mouse horseradish peroxidase conjugate. Both antibodies were
obtained from Transduction Laboratories Inc. (Lexington, KY). 
Data collection
X-ray diffraction data sets were collected using a Rigaku RU-200 rotat-
ing anode X-ray generator (CuKα) operated at 50 kV and 100 mA and
equipped with Supper focusing mirrors and a MAR345 MAR Research
image plate detector. Data collection on frozen crystals was performed
by transferring a crystal into a cryoprotectant solution (100 mM Hepes
at pH 7.2, 2.2 M (NH4)2SO4, 0.6 M sucrose, 0.55 M glucose, and 2%
(v/v) monomethylether polyethylene glycol MW = 550 kDa), flash freez-
ing the crystal in liquid nitrogen, and then transferring the frozen crystal
into a stream of nitrogen at –186°C. Data were integrated and scaled
using the programs DENZO and SCALEPACK [48] Data-collection
statistics are given in Table 2. 
Structure determination and refinement
Initial protein phases were obtained using the AMoRe molecular-
replacement program [49], molecule 1 of the FGFR1 structure [30]
(PDB entry 1FGK) as a search probe, and the native1 data set. The
correct solution was achieved by including the FGFR1 sidechains
and removing mobile residues of the activation loop (640–660), the
N terminus (464–467), a short loop (517–520), and the C termius
(760–762) from the search model. The correct solution was the top
peak in the rotation and translation functions and had a correlation
coefficient of 0.31. Rigid-body refinement in AMoRe improved the
solution to a correlation coefficient of 0.49 and an R factor of 46.3%
in the 12.0–4.0 Å resolution range. The correctness of this solution was
cross-checked by calculation of a difference Fourier with a KAu(CN)2
derivative. This derivative was generated by soaking a crystal for
three days in reservoir solution containing 0.5 mM KAu(CN)2 and then
increasing the heavy-atom concentration to 5 mM and soaking for an
additional 64 h. Scaling of data sets, Patterson calculations, Fourier
calculations, and the generation of phases were performed using the
program package Xtalview [50].
Refinement of the model was carried out using X-PLOR version 3.1
[51]. Calculation of electron-density maps and model fitting was per-
formed using XtalView [50]. Refinement was begun using a data set
collected at 4°C (native2) and was completed using a data set
(native3) collected at –186 °C. The final R factor is 20.2% for data in
the range 8–2.4 Å (Fo > 2σ). The average B value for all atoms is
31.8 Å2 for protein atoms and 42.8 Å2 for water molecules. The final
model includes residues 820–939, 998–1047, and 1064–1168. Of
these residues, the sidechains of K838, R842, F845, Y938, K939,
D998, K1023, R1027, Y1038, K1039, K1110, and E1113 could not
be modeled beyond Cβ because of a lack of interpretable density.
Analysis of mainchain torsion angles using PROCHECK [52] shows
that, of the 275 residues in the model, none occurs in the disallowed
region and only four occur in the generously allowed region of a
Ramachandran plot. Water molecules, of which there were 182, were
fit to electron-density peaks that were greater than 3σ and were
located in positions for making reasonable hydrogen bonds to the
protein or other water molecules. Superpositions of various kinase
structures were performed using the graphics program Insight II (Mol-
ecular Simulations Inc., San Diego, CA) [53].
Accession numbers
The coordinates for VEGFR2∆50P have been deposited in the Protein
Data Bank with accession code 1vr2 and will be available one year
after the publication date of this article.
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